$72.85 Million in Sales Expected for Amarin Co. plc (AMRN) This Quarter

Share on StockTwits

Wall Street brokerages forecast that Amarin Co. plc (NASDAQ:AMRN) will announce $72.85 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Amarin’s earnings, with the lowest sales estimate coming in at $65.90 million and the highest estimate coming in at $79.80 million. Amarin posted sales of $43.92 million during the same quarter last year, which indicates a positive year-over-year growth rate of 65.9%. The company is scheduled to issue its next quarterly earnings report on Wednesday, May 1st.

On average, analysts expect that Amarin will report full year sales of $368.85 million for the current year, with estimates ranging from $351.70 million to $386.00 million. For the next year, analysts forecast that the business will post sales of $589.20 million, with estimates ranging from $515.00 million to $663.40 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that follow Amarin.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $77.30 million during the quarter, compared to analysts’ expectations of $73.87 million. The company’s revenue was up 43.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.08) EPS.

Several equities analysts recently issued reports on the company. Citigroup reduced their price target on Amarin to $20.00 in a research report on Tuesday, January 8th. SunTrust Banks restated a “buy” rating on shares of Amarin in a research report on Monday, January 7th. Cantor Fitzgerald set a $35.00 price target on Amarin and gave the stock a “buy” rating in a research report on Friday, December 28th. Jefferies Financial Group set a $30.00 price target on Amarin and gave the stock a “buy” rating in a research report on Thursday, December 20th. Finally, BidaskClub upgraded Amarin from a “hold” rating to a “buy” rating in a research report on Tuesday, November 27th. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Amarin has an average rating of “Buy” and a consensus target price of $32.17.

In other Amarin news, insider Steven B. Ketchum sold 17,041 shares of the stock in a transaction that occurred on Monday, December 31st. The stock was sold at an average price of $13.51, for a total value of $230,223.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lars Ekman sold 135,377 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $21.31, for a total value of $2,884,883.87. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,841,072 shares of company stock worth $49,748,088. 4.08% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. purchased a new stake in Amarin in the 4th quarter worth approximately $34,000. Global Retirement Partners LLC lifted its holdings in Amarin by 266.3% in the 4th quarter. Global Retirement Partners LLC now owns 2,612 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 1,899 shares during the period. Neuburgh Advisers LLC purchased a new stake in Amarin in the 4th quarter worth approximately $36,000. Lindbrook Capital LLC purchased a new stake in Amarin in the 4th quarter worth approximately $40,000. Finally, Amundi Pioneer Asset Management Inc. purchased a new stake in Amarin in the 4th quarter worth approximately $80,000. Institutional investors and hedge funds own 48.30% of the company’s stock.

Shares of Amarin stock traded down $1.25 during trading on Thursday, hitting $17.51. 8,302,168 shares of the stock traded hands, compared to its average volume of 9,473,905. The company has a current ratio of 2.40, a quick ratio of 2.04 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $5.65 billion, a PE ratio of -44.90 and a beta of 1.29. Amarin has a 52 week low of $2.35 and a 52 week high of $23.33.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Recommended Story: How to Invest in an Index Fund

Get a free copy of the Zacks research report on Amarin (AMRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.